Michael A Puskarich1, Jeffrey A Kline2, Virginia Krabill3, Heather Claremont3, Alan E Jones4. 1. Department of Emergency Medicine, University of Mississippi Medical Center, Jackson. 2. Department of Emergency Medicine, University of Indiana School of Medicine, Indianapolis. 3. Department of Emergency Medicine, Carolinas Medical Center, Charlotte, North Carolina. 4. Department of Emergency Medicine, University of Mississippi Medical Center, Jackson aejones@umc.edu.
Abstract
BACKGROUND: Sepsis is characterized by metabolic disturbances, and previous data suggest a relative carnitine deficiency may contribute to metabolic dysfunction. Studies regarding safety and patient-centered efficacy of carnitine during septic shock are lacking. METHODS: This was a double-blind randomized control trial of levocarnitine (L-carnitine) infusion vs normal saline for the treatment of vasopressor-dependent septic shock. Patients meeting consensus definition for septic shock with a cumulative vasopressor index ≥ 3 and sequential organ failure assessment (SOFA) score ≥ 5 enrolled within 16 hours of the recognition of septic shock were eligible. The primary safety outcome was difference in serious adverse events (SAEs) per patient between groups. Efficacy outcomes included proportion of patients demonstrating a decrease in SOFA score of 2 or more points at 24 hours and short- and long-term survival. RESULTS: Of the 31 patients enrolled, 16 were in the L-carnitine and 15 were in the placebo arm. There was no difference in SAEs between placebo and intervention (2.1 vs 1.8 SAEs per patient, P = .44). There was no difference in the proportion of patients achieving a decrease in SOFA score of 2 or more points at 24 hours between placebo and treatment (53% vs 44%, P = .59). Mortality was significantly lower at 28 days in the L-carnitine group (4/16 vs 9/15, P = .048), with a nonsignificant improved survival at 1 year (P = .06). CONCLUSION:L-carnitine infusion appears safe in vasopressor-dependent septic shock. Preliminary efficacy data suggest potential benefit of L-carnitine treatment, and further testing is indicated.
RCT Entities:
BACKGROUND:Sepsis is characterized by metabolic disturbances, and previous data suggest a relative carnitine deficiency may contribute to metabolic dysfunction. Studies regarding safety and patient-centered efficacy of carnitine during septic shock are lacking. METHODS: This was a double-blind randomized control trial of levocarnitine (L-carnitine) infusion vs normal saline for the treatment of vasopressor-dependent septic shock. Patients meeting consensus definition for septic shock with a cumulative vasopressor index ≥ 3 and sequential organ failure assessment (SOFA) score ≥ 5 enrolled within 16 hours of the recognition of septic shock were eligible. The primary safety outcome was difference in serious adverse events (SAEs) per patient between groups. Efficacy outcomes included proportion of patients demonstrating a decrease in SOFA score of 2 or more points at 24 hours and short- and long-term survival. RESULTS: Of the 31 patients enrolled, 16 were in the L-carnitine and 15 were in the placebo arm. There was no difference in SAEs between placebo and intervention (2.1 vs 1.8 SAEs per patient, P = .44). There was no difference in the proportion of patients achieving a decrease in SOFA score of 2 or more points at 24 hours between placebo and treatment (53% vs 44%, P = .59). Mortality was significantly lower at 28 days in the L-carnitine group (4/16 vs 9/15, P = .048), with a nonsignificant improved survival at 1 year (P = .06). CONCLUSION:L-carnitine infusion appears safe in vasopressor-dependent septic shock. Preliminary efficacy data suggest potential benefit of L-carnitine treatment, and further testing is indicated.
Authors: J L Vincent; R Moreno; J Takala; S Willatts; A De Mendonça; H Bruining; C K Reinhart; P M Suter; L G Thijs Journal: Intensive Care Med Date: 1996-07 Impact factor: 17.440
Authors: G Nanni; M Pittiruti; I Giovannini; G Boldrini; P Ronconi; M Castagneto Journal: JPEN J Parenter Enteral Nutr Date: 1985 Jul-Aug Impact factor: 4.016
Authors: Alan E Jones; Ian G Stiell; Lisa P Nesbitt; Daniel W Spaite; Nael Hasan; Brian A Watts; Jeffrey A Kline Journal: Ann Emerg Med Date: 2004-01 Impact factor: 5.721
Authors: Charles R Evans; Alla Karnovsky; Michael A Puskarich; George Michailidis; Alan E Jones; Kathleen A Stringer Journal: J Proteome Res Date: 2019-04-01 Impact factor: 4.466
Authors: Anders Perner; Andrew Rhodes; Bala Venkatesh; Derek C Angus; Ignacio Martin-Loeches; Jean-Charles Preiser; Jean-Louis Vincent; John Marshall; Konrad Reinhart; Michael Joannidis; Steven M Opal Journal: Intensive Care Med Date: 2017-01-27 Impact factor: 17.440
Authors: Andrew Rhodes; Laura E Evans; Waleed Alhazzani; Mitchell M Levy; Massimo Antonelli; Ricard Ferrer; Anand Kumar; Jonathan E Sevransky; Charles L Sprung; Mark E Nunnally; Bram Rochwerg; Gordon D Rubenfeld; Derek C Angus; Djillali Annane; Richard J Beale; Geoffrey J Bellinghan; Gordon R Bernard; Jean-Daniel Chiche; Craig Coopersmith; Daniel P De Backer; Craig J French; Seitaro Fujishima; Herwig Gerlach; Jorge Luis Hidalgo; Steven M Hollenberg; Alan E Jones; Dilip R Karnad; Ruth M Kleinpell; Younsuk Koh; Thiago Costa Lisboa; Flavia R Machado; John J Marini; John C Marshall; John E Mazuski; Lauralyn A McIntyre; Anthony S McLean; Sangeeta Mehta; Rui P Moreno; John Myburgh; Paolo Navalesi; Osamu Nishida; Tiffany M Osborn; Anders Perner; Colleen M Plunkett; Marco Ranieri; Christa A Schorr; Maureen A Seckel; Christopher W Seymour; Lisa Shieh; Khalid A Shukri; Steven Q Simpson; Mervyn Singer; B Taylor Thompson; Sean R Townsend; Thomas Van der Poll; Jean-Louis Vincent; W Joost Wiersinga; Janice L Zimmerman; R Phillip Dellinger Journal: Intensive Care Med Date: 2017-01-18 Impact factor: 17.440
Authors: Michael A Puskarich; Michael A Finkel; Alla Karnovsky; Alan E Jones; Julie Trexel; Brooke N Harris; Kathleen A Stringer Journal: Ann Am Thorac Soc Date: 2015-01
Authors: Michael A Puskarich; Nathan I Shapiro; Michael J Massey; Jeffrey A Kline; Alan E Jones Journal: Acad Emerg Med Date: 2016-05-11 Impact factor: 3.451
Authors: Theodore S Jennaro; Michael A Puskarich; Marc R McCann; Christopher E Gillies; Manjunath P Pai; Alla Karnovsky; Charles R Evans; Alan E Jones; Kathleen A Stringer Journal: Pharmacotherapy Date: 2020-08-10 Impact factor: 4.705
Authors: Michael A Puskarich; Charles R Evans; Alla Karnovsky; Arun K Das; Alan E Jones; Kathleen A Stringer Journal: Shock Date: 2018-04 Impact factor: 3.454
Authors: Harm-Jan de Grooth; Jonne Postema; Stephan A Loer; Jean-Jacques Parienti; Heleen M Oudemans-van Straaten; Armand R Girbes Journal: Intensive Care Med Date: 2018-03-15 Impact factor: 17.440